BioSpace News Archive

physIQ, a pioneer in digital medicine, and CellCarta, a global leader in precision medicine services, announce a strategic collaboration to undertake a groundbreaking study with the potential to revolutionize vaccine development.

Enveda Biosciences, a leading biotechnology company harnessing nature’s chemistry to develop next-generation small molecule therapies, announced the addition of three leaders to further scale and accelerate its translational drug development efforts.

Deepcell today announced that it has closed its $73 million Series B round of financing.

Guardant Health, Inc. today provided the following statement regarding a lawsuit filed by Illumina that seeks to challenge Guardant Health’s ownership and authorship of a portion of its intellectual property and to suppress competition in the market.

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), today announced that physicians at the Clinica Porto Azul in Barranquilla, Colombia successfully implanted the Company’s PortIO™ Intraosseous Infusion System in three patients—the first human implants of the device—as part of its IRB-approved first-in-human (FIH) clinical study of up to 40 patients.

Supernus Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, filed a notification of Late Filing on Form 12b-25 on March 1, 2022, indicating that the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2021 would be delayed.

Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), today announced that the first patient has been dosed in a Phase 3 clinical trial to assess the safety, efficacy and tolerability of DFD-29 (Minocycline Modified Release Capsules 40 mg).

CorMedix Inc. today announced the appointment of Joseph Todisco as Chief Executive Officer of the company.

Medtronic plc, a global leader in healthcare technology, announced leadership transitions for three of its Operating Units – Diabetes, Surgical Robotics, and Cardiac Rhythm Management – bringing in critical skills and capabilities and creating opportunities for internal talent.

TC Biopharm announces orphan drug status has been granted for lead product OmnImmune® for use in Acute Myeloid Leukemia (“AML”).